Reuters exclusively reported that Eli Lilly & Co employees have accused a factory executive of altering documents required by government regulators in an effort to downplay serious quality control problems at the U.S. plant producing the drugmaker’s COVID-19 treatment. An internal complaint asserts that an official at the company rewrote findings by technical experts to make the conclusions appear more favorable to the company.
Health
Reuters exclusively reports Lilly hit by staff accusations, FDA scrutiny at COVID drug factories
05 May 2021, 2:09 pm 1 minute
Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: North America
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story